Psoriatic Arthritis
Conditions
Keywords
Psoriatic Arthritis
Brief summary
An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country study in participants with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 (Day 1 up to Week 16) is designed to compare the achievement of minimal disease activity (MDA) between participants randomized to either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the highest recommended or tolerable dose; Part 2 (Week 16 through Week 32) is designed to evaluate the maintenance or achievement of MDA on 4 different treatment regimens using adalimumab and/or MTX, with participant allocation based on the initial randomized treatment and achievement of MDA in Part 1, and with rescue treatment option.
Interventions
DRUGmethotrexate (MTX)
BIOLOGICALadalimumab (ADA)
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. PsA diagnosis established at least 4 weeks prior to the date of the Screening visit and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria 2. Not in MDA at the time of screening 3. Has 3 or more tender and 3 or more swollen joints 4. Treated with methotrexate 15 mg (weekly) for at least 4 weeks
Exclusion criteria
1. Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab or its excipients 2. History of methotrexate intolerance/toxicity 3. Medical conditions(s) precluding methotrexate dose increase above 15 mg 4. Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of action biologic DMARD (bDMARD) or any systemic biologic agent in general
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1) | Week 16 | Minimal disease activity (MDA) for psoriatic arthritis (PsA) was defined as fulfilling at least 5 of the following 7 criteria: tender and swollen joint counts (TJC) ≤ 1 (out of TJC68 assessed in this study), swollen joint count (SJC) ≤ 1 (out of SJC66 assessed in this study), Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3; Patient's assessment of pain visual analogue scale (VAS) ≤ 15, Patient's global assessment of disease activity (PtGA) VAS ≤ 20, Health Assessment Questionnaire Disability Index (HAQ-DI) score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1) | From Day 1 to Week 16 | Hands and feet bilaterally were assessed for the presence/absence of dactylitis and associated tenderness for participants with presence of dactylitis at baseline. The tender dactylitic digit count is equal to the number of swollen and painful digits (range 0 to 20). A decrease indicates improvement. |
| Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1) | From Day 1 to Week 16 | The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity but is also used in PsA clinical trials. DAS28 is a composite score calculated using a mathematical formula based on the scores for these scales. DAS28 includes tender and swollen joint counts, PtGA, and acute phase reactant (CRP in this study). DAS28 scores range from 0 to 10, with higher scores indicating more disease activity. A larger negative change in the DAS28 score indicates greater improvement. |
| Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1) | From Day 1 to Week 16 | Psoriatic Arthritis Impact of Disease Score (PsAID) was developed by an European League Against Rheumatism (EULAR) initiative and is a validated patient self-reported tool to assess the impact of PsA on the participant's life. The PsAID is a composite score calculated using a mathematical formula based on the scores for each component. PsAID-9 was developed for clinical trials and was used in this study. The PsAID-9 is calculated based on 9 Numerical rating scales (NRS) questions that include pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, and anxiety). Each NRS is assessed as a number between 0 and 10. PsAID scores range from 0 to 10, with higher scores indicating worse status. A larger negative change in the PsAID-9 score indicates greater improvement. |
| Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1) | Week 16 | The ACR is a standard criteria originally developed to measure the effectiveness of various arthritis medications or treatments in clinical trials for RA, but is also widely used in PsA. The ACR measures improvement in tender joint count (TJC) or swollen joint count (SJC), and improvement in at least 3 of the following 5 parameters: Patient Global Assessment (PtGA), Physician's Global Assessment of Disease Activity (PhGA), physical function (using HAQ-DI) and acute phase reactant (using CRP). ACR 20/50/70 response is achieved if ≥ 20%/≥ 50%/≥ 70% improvement in tender joint count (TJC) or swollen joint count (SJC) as well as a ≥ 20%/≥ 50%/≥ 70% improvement in ≥ 3 of the other 5 parameters. |
| Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline | From Day 1 to Week 16 | The Leeds Enthesitis Index (LEI) is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions for participants with presence of LEI at baseline.Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 sites, for an overall score range of 0 to 6. A decrease in LEI indicates improvement. |
| Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1) | From Day 1 to Week 16 | The Dermatology Life Quality Index (DLQI) score is a measure of participant's quality of life (QOL) related to skin disease.The DLQI questionnaire consists of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health related QOL over the last week. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. The range of possible DLQI scores is 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement. |
| Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1) | From Day 1 to week 16 | Psoriatic Arthritis Disease Activity Score (PASDAS) is a weighted disease activity measure developed specifically for PsA. It includes PhGA, PtGA, SF-36 PCS, SJC, TJC, Leeds enthesitis count, tender dactylitic count and hsCRP lab test. The PASDAS is a composite score calculated using a mathematical formula based on the scores for each component. The PASDAS is unitless, with a typical score range between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement. . |
| Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1) | From Day 1 to Week 16 | The Short Form Health Survey 36 (SF-36) is a generic measure to assess participant's general health/well-being (health related quality of life); short version 2 (SF-36v2) was used. SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise physical component of the SF-36. Scores on each item were summed and averaged (PCS; range = 0-100). Items 5-8 comprise mental component of the SF-36. Scores on each item were summed and averaged (mental component score \[MCS\]; range = 0-100). Larger values on SF-36 indicate a better condition. A positive change from Baseline in either PCS or MCS indicates improvement. |
| Change in HAQ-DI Score From Baseline (Part 1) | From Day 1 to Week 16 | The HAQ-DI is a standardized measure of physical function in arthritis. The HAQ-DI questionnaire contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement. |
| Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1) | Week 16 | Psoriasis Area and Severity Index (PASI) provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. 75/90/100 denotes greater than or equal to 75%/90%/100% improvement in PASI score. A 100% reduction is considered complete clearance of psoriasis. |
| Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1) | From Day 1 to Week 16 | Disease Activity in Psoriatic Arthritis Score (DAPSA) score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity. |
| Percentage of Participants in MDA in Part 2 of the Study (Week 32) | Week 32 | MDA for PsA was defined as fulfilling at least 5 of the following 7 criteria: TJC ≤ 1 (out of TJC68 assessed in this study), SJC ≤ 1 (out of SJC66 assessed in this study), PASI ≤ 1 or BSA ≤ 3; Patient's assessment of pain VAS ≤ 15, PtGA VAS ≤ 20, HAQ-DI score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study). |
Countries
Australia, Brazil, Bulgaria, Canada, Colombia, Czechia, Germany, Italy, Poland, Puerto Rico, Qatar, Spain, United Kingdom, United States
Participant flow
Recruitment details
There were 246 participants randomized; 1 participant did not receive study medication. Upon completion of Part 1, eligible participants continued to Part 2, so no additional participants were enrolled in Part 2.
Pre-assignment details
Intent-To-Treat Part 1 (ITT Part 1) population comprised all participants randomized and received at least 1 dose of study medication in Part 1. ITT Long Term (ITT LT) population included all participants who continued to Part 2 and received at least 1 dose of Part 2 study medication; no additional participants were enrolled into Part 2.
Participants by arm
| Arm | Count |
|---|---|
| Part 1: MTX Escalated Dose Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew) | 122 |
| Part 1: ADA + MTX Adalimumab (ADA) 40 mg every other week (eow) in combination with methotrexate (MTX) 15 mg every week (ew) | 123 |
| Total | 245 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Part 1 | Adverse Event | 2 | 3 | 0 | 0 | 0 | 0 |
| Part 1 | Lack of Efficacy | 1 | 2 | 0 | 0 | 0 | 0 |
| Part 1 | Lost to Follow-up | 1 | 0 | 0 | 0 | 0 | 0 |
| Part 1 | Withdrawal Consent | 8 | 1 | 0 | 0 | 0 | 0 |
| Part 2 | Adverse Event | 0 | 0 | 0 | 1 | 1 | 2 |
| Part 2 | Lack of Efficacy | 0 | 0 | 0 | 0 | 0 | 3 |
| Part 2 | Lost to Follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
| Part 2 | Withdrawal Consent | 0 | 0 | 0 | 2 | 1 | 1 |
Baseline characteristics
| Characteristic | Part 1: ADA + MTX | Total | Part 1: MTX Escalated Dose |
|---|---|---|---|
| Age, Continuous | 51.4 years STANDARD_DEVIATION 12.23 | 50.1 years STANDARD_DEVIATION 12.5 | 48.8 years STANDARD_DEVIATION 12.69 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 27 Participants | 54 Participants | 27 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 96 Participants | 191 Participants | 95 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 8 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 4 Participants | 6 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 115 Participants | 226 Participants | 111 Participants |
| Sex: Female, Male Female | 64 Participants | 123 Participants | 59 Participants |
| Sex: Female, Male Male | 59 Participants | 122 Participants | 63 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 122 | 0 / 123 | 0 / 15 | 0 / 95 | 0 / 54 | 0 / 63 |
| other Total, other adverse events | 32 / 122 | 24 / 123 | 5 / 15 | 25 / 95 | 5 / 54 | 20 / 63 |
| serious Total, serious adverse events | 0 / 122 | 2 / 123 | 0 / 15 | 3 / 95 | 1 / 54 | 3 / 63 |
Outcome results
Primary
Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1)
Minimal disease activity (MDA) for psoriatic arthritis (PsA) was defined as fulfilling at least 5 of the following 7 criteria: tender and swollen joint counts (TJC) ≤ 1 (out of TJC68 assessed in this study), swollen joint count (SJC) ≤ 1 (out of SJC66 assessed in this study), Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3; Patient's assessment of pain visual analogue scale (VAS) ≤ 15, Patient's global assessment of disease activity (PtGA) VAS ≤ 20, Health Assessment Questionnaire Disability Index (HAQ-DI) score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).
Time frame: Week 16
Population: Intent-To-Treat Part 1 (ITT Part 1) population comprises all participants who were randomized and received at least one dose of the study medication during Part 1. Results for binary endpoints are based on non-responder imputation (NRI).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: MTX Escalated Dose | Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1) | 13.1 percentage of participants |
| Part 1: ADA + MTX | Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1) | 41.5 percentage of participants |
p-value: <0.00195% CI: [17.8, 38.9]Cochran-Mantel-Haenszel
Secondary
Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1)
The Dermatology Life Quality Index (DLQI) score is a measure of participant's quality of life (QOL) related to skin disease.The DLQI questionnaire consists of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health related QOL over the last week. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. The range of possible DLQI scores is 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.
Time frame: From Day 1 to Week 16
Population: ITT (Part 1). Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part 1: MTX Escalated Dose | Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1) | -3.1 score on a scale |
| Part 1: ADA + MTX | Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1) | -5.9 score on a scale |
Secondary
Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1)
Disease Activity in Psoriatic Arthritis Score (DAPSA) score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity.
Time frame: From Day 1 to Week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part 1: MTX Escalated Dose | Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1) | -12.1 score on a scale |
| Part 1: ADA + MTX | Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1) | -28.2 score on a scale |
Secondary
Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1)
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity but is also used in PsA clinical trials. DAS28 is a composite score calculated using a mathematical formula based on the scores for these scales. DAS28 includes tender and swollen joint counts, PtGA, and acute phase reactant (CRP in this study). DAS28 scores range from 0 to 10, with higher scores indicating more disease activity. A larger negative change in the DAS28 score indicates greater improvement.
Time frame: From Day 1 to Week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part 1: MTX Escalated Dose | Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1) | -0.9 score on a scale |
| Part 1: ADA + MTX | Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1) | -2.0 score on a scale |
Secondary
Change in HAQ-DI Score From Baseline (Part 1)
The HAQ-DI is a standardized measure of physical function in arthritis. The HAQ-DI questionnaire contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement.
Time frame: From Day 1 to Week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part 1: MTX Escalated Dose | Change in HAQ-DI Score From Baseline (Part 1) | -0.3 score on a scale |
| Part 1: ADA + MTX | Change in HAQ-DI Score From Baseline (Part 1) | -0.5 score on a scale |
Secondary
Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline
The Leeds Enthesitis Index (LEI) is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions for participants with presence of LEI at baseline.Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 sites, for an overall score range of 0 to 6. A decrease in LEI indicates improvement.
Time frame: From Day 1 to Week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part 1: MTX Escalated Dose | Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline | -1.1 score on a scale |
| Part 1: ADA + MTX | Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline | -1.9 score on a scale |
Secondary
Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1)
Psoriatic Arthritis Disease Activity Score (PASDAS) is a weighted disease activity measure developed specifically for PsA. It includes PhGA, PtGA, SF-36 PCS, SJC, TJC, Leeds enthesitis count, tender dactylitic count and hsCRP lab test. The PASDAS is a composite score calculated using a mathematical formula based on the scores for each component. The PASDAS is unitless, with a typical score range between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement. .
Time frame: From Day 1 to week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part 1: MTX Escalated Dose | Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1) | -1.2 score on a scale |
| Part 1: ADA + MTX | Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1) | -2.8 score on a scale |
Secondary
Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1)
Psoriatic Arthritis Impact of Disease Score (PsAID) was developed by an European League Against Rheumatism (EULAR) initiative and is a validated patient self-reported tool to assess the impact of PsA on the participant's life. The PsAID is a composite score calculated using a mathematical formula based on the scores for each component. PsAID-9 was developed for clinical trials and was used in this study. The PsAID-9 is calculated based on 9 Numerical rating scales (NRS) questions that include pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, and anxiety). Each NRS is assessed as a number between 0 and 10. PsAID scores range from 0 to 10, with higher scores indicating worse status. A larger negative change in the PsAID-9 score indicates greater improvement.
Time frame: From Day 1 to Week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part 1: MTX Escalated Dose | Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1) | -1.7 score on a scale |
| Part 1: ADA + MTX | Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1) | -3.3 score on a scale |
Secondary
Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1)
The Short Form Health Survey 36 (SF-36) is a generic measure to assess participant's general health/well-being (health related quality of life); short version 2 (SF-36v2) was used. SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise physical component of the SF-36. Scores on each item were summed and averaged (PCS; range = 0-100). Items 5-8 comprise mental component of the SF-36. Scores on each item were summed and averaged (mental component score \[MCS\]; range = 0-100). Larger values on SF-36 indicate a better condition. A positive change from Baseline in either PCS or MCS indicates improvement.
Time frame: From Day 1 to Week 16
Population: ITT (Part 1)
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Part 1: MTX Escalated Dose | Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1) | SF-36 PCS | 4.4 score on a scale |
| Part 1: MTX Escalated Dose | Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1) | SF-36 MCS | 1.3 score on a scale |
| Part 1: ADA + MTX | Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1) | SF-36 PCS | 8.9 score on a scale |
| Part 1: ADA + MTX | Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1) | SF-36 MCS | 4.4 score on a scale |
Secondary
Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1)
Hands and feet bilaterally were assessed for the presence/absence of dactylitis and associated tenderness for participants with presence of dactylitis at baseline. The tender dactylitic digit count is equal to the number of swollen and painful digits (range 0 to 20). A decrease indicates improvement.
Time frame: From Day 1 to Week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Part 1: MTX Escalated Dose | Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1) | -0.9 count of fingers/ toes with dactylitis |
| Part 1: ADA + MTX | Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1) | -2.8 count of fingers/ toes with dactylitis |
Secondary
Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1)
The ACR is a standard criteria originally developed to measure the effectiveness of various arthritis medications or treatments in clinical trials for RA, but is also widely used in PsA. The ACR measures improvement in tender joint count (TJC) or swollen joint count (SJC), and improvement in at least 3 of the following 5 parameters: Patient Global Assessment (PtGA), Physician's Global Assessment of Disease Activity (PhGA), physical function (using HAQ-DI) and acute phase reactant (using CRP). ACR 20/50/70 response is achieved if ≥ 20%/≥ 50%/≥ 70% improvement in tender joint count (TJC) or swollen joint count (SJC) as well as a ≥ 20%/≥ 50%/≥ 70% improvement in ≥ 3 of the other 5 parameters.
Time frame: Week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part 1: MTX Escalated Dose | Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1) | ACR 20 | 32.8 percentage of participants |
| Part 1: MTX Escalated Dose | Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1) | ACR 50 | 16.4 percentage of participants |
| Part 1: MTX Escalated Dose | Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1) | ACR 70 | 8.2 percentage of participants |
| Part 1: ADA + MTX | Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1) | ACR 20 | 67.5 percentage of participants |
| Part 1: ADA + MTX | Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1) | ACR 50 | 45.5 percentage of participants |
| Part 1: ADA + MTX | Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1) | ACR 70 | 30.9 percentage of participants |
Secondary
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1)
Psoriasis Area and Severity Index (PASI) provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. 75/90/100 denotes greater than or equal to 75%/90%/100% improvement in PASI score. A 100% reduction is considered complete clearance of psoriasis.
Time frame: Week 16
Population: ITT (Part 1) Results for binary endpoints are based on NRI. Results for other continuous endpoints are based on MMRM.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part 1: MTX Escalated Dose | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1) | PASI 75 | 31.0 percentage of participants |
| Part 1: MTX Escalated Dose | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1) | PASI 90 | 18.4 percentage of participants |
| Part 1: MTX Escalated Dose | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1) | PASI 100 | 9.2 percentage of participants |
| Part 1: ADA + MTX | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1) | PASI 75 | 73.1 percentage of participants |
| Part 1: ADA + MTX | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1) | PASI 90 | 57.7 percentage of participants |
| Part 1: ADA + MTX | Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1) | PASI 100 | 29.5 percentage of participants |
Secondary
Percentage of Participants in MDA in Part 2 of the Study (Week 32)
MDA for PsA was defined as fulfilling at least 5 of the following 7 criteria: TJC ≤ 1 (out of TJC68 assessed in this study), SJC ≤ 1 (out of SJC66 assessed in this study), PASI ≤ 1 or BSA ≤ 3; Patient's assessment of pain VAS ≤ 15, PtGA VAS ≤ 20, HAQ-DI score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).
Time frame: Week 32
Population: ITT Long Term (ITT LT) population comprises all participants who continued to Part 2 and received at least one dose of Part 2 study medication. No missing data imputationperformed for long term efficacy analysis except for participants who were rescued, where participants rescued prior to Week 32 are imputed as non-responders.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: MTX Escalated Dose | Percentage of Participants in MDA in Part 2 of the Study (Week 32) | 66.7 percentage of participants |
| Part 1: ADA + MTX | Percentage of Participants in MDA in Part 2 of the Study (Week 32) | 54.9 percentage of participants |
| Part 2: ADA | Percentage of Participants in MDA in Part 2 of the Study (Week 32) | 80.4 percentage of participants |
| Part 2: ADA ew + MTX | Percentage of Participants in MDA in Part 2 of the Study (Week 32) | 29.8 percentage of participants |